JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2004; 44:959-966, doi:10.1016/j.jacc.2004.05.070
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Felker, G.M.
Right arrow Articles by O'Connor, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Felker, G.M.
Right arrow Articles by O'Connor, C. M.

Anemia as a risk factor and therapeutic target in heart failure

G.Michael Felker, MD*,*, Kirkwood F. Adams, Jr, MD, FACC{dagger}, Wendy A. Gattis, PharmD* and Christopher M. O'Connor, MD, FACC*

* Duke Clinical Research Institute, Durham, North Carolina, USA
{dagger} University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA



View larger version (22K):

[in a new window]
  		Figure 1 A conceptual model of mechanismsinvolved in the interaction between heart failure, renal function, bone marrow, and anemia. ACE = angiotensin-converting enzyme; EPO = erythropoietin; LVH = left ventricular hypertrophy; RAS = renin-angiotensin system; RBC = red blood cell; TNF = tumor necrosis factor.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.